The 17 most recent market catalysts affecting $CVS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Market Technicals
Bearish
Impact 55
Top 3 Health Care Stocks That May Rocket Higher In September
Benzinga Pro has identified CVS Health Corp, Steris PLC, and Baxter International Inc as oversold in the healthcare sector, with RSI values below 30. This technical indicator sugge…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 55
CVS Health's Aetna Reduces Administrative Tasks For Cancer Care
CVS Health's Aetna is expanding its bundled prior authorization program for all cancer types, initially for Medicaid members and eventually across all business lines by 2027. This …
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 55
CVS Health Unit Aetna Announces Expansion Of Prior Authorization Bundles Across All Cancer Types For Members In Eligible Medicaid States As Of September 1, With Plans To Expand Across All Lines Of Business In 2027
CVS Health's Aetna unit is expanding its bundled prior authorization program for cancer treatments, initially for Medicaid members in specific states, with a full rollout across al…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 55
Guardian Pharmacy Services Announces Acquisition Of Assets From Nautilus Pharmacy, Including Prescription Files And Inventory; Terms Not Disclosed
This acquisition is a corporate catalyst, indicating consolidation within the specialized pharmacy sector, specifically long-term care. While the financial terms are not disclosed,…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 55
Argus Research Maintains Buy on CVS Health, Raises Price Target to $114
Argus Research, through analyst Steve Silver, has maintained its 'Buy' rating on CVS Health and raised its price target from $104 to $114. This action signals a continued bullish s…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 85
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
CVS Health delivered a robust second-quarter performance, surpassing Wall Street's estimates and prompting an upward revision of its fiscal 2026 adjusted earnings guidance. This fi…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
CVS Health shares are trading lower despite reporting better-than-expected Q2 financial results and raising its FY26 adjusted EPS guidance above estimates. The stock may be experiencing some profit taking after rising almost 60% from the end of Q1.
This headline indicates a classic 'sell the news' or profit-taking scenario. Even though CVS Health delivered strong financial results and raised future guidance, the stock's subst…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
CVS shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 EPS guidance. Also, the company issued FY26 revenue guidance above estimates.
This headline represents a significant positive corporate catalyst for CVS. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26 EPS and revenue) si…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
CVS stock has given up its prior gain. CVS shares were trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 EPS guidance. Also, the company issued FY26 revenue guidance above estimates.
This headline indicates a significant corporate catalyst for CVS, as strong Q2 results and raised FY26 guidance are typically very positive. The 'giving up' of gains, however, sugg…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
CVS Health Exec Says Co. Will See Membership Declines In Care Mark Next Year
CVS Health's executive team, during a conference call, indicated an expected decline in membership for its Caremark pharmacy benefit management (PBM) segment next year. This is a s…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000M vs $409.235B Est
CVS Health announced a substantial increase in its fiscal year 2026 adjusted EPS guidance from $7.30-$7.50 to $7.90-$8.10, significantly exceeding the analyst estimate of $7.45. Co…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est
This headline is a significant corporate catalyst for CVS Health. The upward revision of both EPS and revenue guidance for FY2026, particularly the substantial increase in EPS, ind…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Health Retools Its Weight Management Program To Make It Easier For Eligible Adults To Access Clinical Care, Navigate Medication Costs And Get Ongoing Support For GLP-1 Therapy
CVS Health is strategically retooling its weight management program to capitalize on the booming GLP-1 market. By offering all FDA-approved GLP-1s, collaborating with Eli Lilly for…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion
CVS Health's Caremark subsidiary has reached a settlement with the FTC, resolving a significant antitrust case that alleged rebate-driven practices artificially inflated drug price…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Health's CVS Caremark Announces Settlement With U.S. Federal Trade Commission To Resolve All Outstanding Litigation, Probe
CVS Health's CVS Caremark has reached a global settlement with the FTC, addressing all pending litigation and investigations. This is significant because it removes a cloud of regu…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on CVS Health, Raises Price Target to $123
Wells Fargo analyst Stephen Baxter maintained an 'Overweight' rating on CVS Health and raised the price target from $103 to $123. This upgrade signals increased confidence from a m…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 65
Federal Health Watchdog Projects $5.56 Billion in Recoveries and Savings, Despite Enforcement Hitting Two-Year Low
The HHS OIG's report highlights a significant projected recovery of $5.56 billion, primarily from enforcement actions against healthcare providers and insurers. While overall enfor…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.